Bhavya S Doshi1,2, Leslie J Raffini1,2, Lindsey A George1,2,3. 1. Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 2. Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA. 3. Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Abstract
BACKGROUND: Hemophilia A (HA) inhibitor patients that fail traditional immune tolerance induction (ITI) have increased morbidity and mortality. Preclinical studies support factor VIII (FVIII) tolerance induction with a combined approach of anti-CD20 mediated transient B cell depletion and rapamycin mediated regulatory T cell (Treg) induction. METHODS: Two refractory HA inhibitor patients were treated with rituximab, rapamycin, and FVIII ITI. Their clinical course, anti-FVIII immunoglobulins, cytokines, and select lymphocytes were followed. RESULTS: One patient achieved complete and the other partial FVIII tolerance; both had marked annualized bleeding rate improvement. FVIII-specific immunoglobulins, but not total Treg counts, correlated with tolerance induction. IL-6 and IL-21 correlation with complete tolerance induction may support that down-regulation of T effectors and IgG4 production, respectively, contribute to the pathogenesis of tolerance induction. CONCLUSIONS: This regimen may be considered to induce FVIII tolerance in HA patients with refractory inhibitors. Further characterization of the FVIII-specific immune response is necessary to clarify the mechanism of immune tolerance.
BACKGROUND:Hemophilia A (HA) inhibitor patients that fail traditional immune tolerance induction (ITI) have increased morbidity and mortality. Preclinical studies support factor VIII (FVIII) tolerance induction with a combined approach of anti-CD20 mediated transient B cell depletion and rapamycin mediated regulatory T cell (Treg) induction. METHODS: Two refractory HA inhibitor patients were treated with rituximab, rapamycin, and FVIII ITI. Their clinical course, anti-FVIII immunoglobulins, cytokines, and select lymphocytes were followed. RESULTS: One patient achieved complete and the other partial FVIII tolerance; both had marked annualized bleeding rate improvement. FVIII-specific immunoglobulins, but not total Treg counts, correlated with tolerance induction. IL-6 and IL-21 correlation with complete tolerance induction may support that down-regulation of T effectors and IgG4 production, respectively, contribute to the pathogenesis of tolerance induction. CONCLUSIONS: This regimen may be considered to induce FVIII tolerance in HApatients with refractory inhibitors. Further characterization of the FVIII-specific immune response is necessary to clarify the mechanism of immune tolerance.
Authors: Charles R M Hay; Ben Palmer; Elizabeth Chalmers; Ri Liesner; Rhona Maclean; Savita Rangarajan; Michael Williams; Peter W Collins Journal: Blood Date: 2011-04-06 Impact factor: 22.113
Authors: P W Collins; M Mathias; J Hanley; D Keeling; R Keenan; M Laffan; D Perry; R Liesner Journal: J Thromb Haemost Date: 2009-03-05 Impact factor: 5.824
Authors: Moanaro Biswas; Geoffrey L Rogers; Alexandra Sherman; Barry J Byrne; David M Markusic; Haiyan Jiang; Roland W Herzog Journal: Thromb Haemost Date: 2016-09-29 Impact factor: 5.249
Authors: C Leissinger; C D Josephson; S Granger; B A Konkle; R Kruse-Jarres; M V Ragni; J M Journeycake; L Valentino; N S Key; J C Gill; K R McCrae; E J Neufeld; C Manno; L Raffini; K Saxena; M Torres; V Marder; C M Bennett; S F Assmann Journal: Thromb Haemost Date: 2014-06-12 Impact factor: 5.249